All News

Found 704,024 articles

• Blaine Labs Issues Voluntary Nationwide Recall of RevitaDerm Wound Care Gel Due to Bacterial Contamination

  1/27/2022

  Blaine Labs Company is voluntarily recalling one lot of RevitaDerm Wound Care to the consumer level because a bottle of the 1.0 ounce RevitaDerm Wound Care Gel has been found to be contaminated with Bacillus cereus.

• Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

  1/27/2022

  Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to USD $2.3 billion.

• Ensysce Biosciences Announces Results of Special Meeting of Stockholders

  1/27/2022

  Ensysce Biosciences, Inc. today announced the results of the special meeting of stockholders held January 26, 2022.

• Applied Molecular Transport Announces Board Appointments

  1/27/2022

  Applied Molecular Transport Inc. today announced the appointment of John W. Smither to its Board of Directors and Chair of its Audit Committee. AMT also announced that current Director, Graham K. Cooper, has been named Executive Chair and current Director, Helen S. Kim, has been named Lead Independent Director.

• Salona Global Medical Device Corporation Announces $4 Million Bought Deal Private Placement

  1/27/2022

  Salona Global Medical Device is pleased to announce that it has entered into an agreement with a syndicate of underwriters pursuant to which the Underwriters have agreed to purchase for resale, on a bought deal private placement basis an aggregate of 7,280,000 units ("Units") at a price of $0.55 per Unit (the "Issue Price") for aggregate gross proceeds to the Company of $4,004,000 (the "Offering").

• SciSparc Presents New Leadership Lineup

  1/27/2022

  SciSparc Ltd. announced that its board of directors (the "Board") resolved to appoint Mr. Oz Adler as the Chief Executive Officer, Mr. Itschak Shrem as the President of the Company and Mr. Amitay Weiss as the chairman of the Board of Directors of the Company, effective January 10, 2022.

• LUNGevity Partners with ALK Positive to Award $1.5 Million in Lung Cancer Research Grants

  1/27/2022

  LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the ALK-Positive Lung Cancer Research Award Program.

• NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts General Hospital

  1/27/2022

  NeuroSense Therapeutics Ltd. announced today the initiation of the third stage of a collaborative biomarker study with Massachusetts General Hospital (MGH).

• SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China

  1/27/2022

  SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced that an IND application to initiate the first clinical trial in China for 3D189, also known as SELLAS’ galinpepimut-S, has been accepted by China’s National Medical Products Administration.

• AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures

  1/27/2022

  AcelRx Pharmaceuticals, Inc. today announced the publication of an article reviewing the use of sufentanil sublingual tablet (SST; DSUVIA ® ) for pain medicine procedures by lead author Dr. Sarang Koushik in Current Pain and Headache Reports.

• Trinity Biotech Announces The Successful Closing of its Debt Refinancing

  1/27/2022

  Trinity Biotech plc today announced that it has closed its recently announced refinancing.

• Numinus Identified as a Licensed Psilocybin Supplier by Health Canada

  1/27/2022

  Numinus Wellness Inc. is pleased to announce that its research facility, Numinus Bioscience, has been included on Health Canada's list of federally licensed psilocybin producers.

• Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis

  1/27/2022

  Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout of Biogen's stake in the Samsung Bioepis joint venture for USD $2.3 billion.

• Taro Provides Results for December 31, 2021

  1/27/2022

  Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2021.

• MoMMA's Voices Awarded New Funding to Further Amplify BIPOC and Other Historically Marginalized Patient Voices in Maternal Health

  1/27/2022

  The Preeclampsia Foundation announced today that Merck for Mothers has awarded new funding for its program, MoMMA's Voices, a national coalition of patient advocacy organizations and individuals with "lived experience" – or those that represent them.

• HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

  1/27/2022

  HaemaLogiX Ltd (HaemaLogiX), and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab.

• Quipt Home Medical Reports Record Fourth Quarter and Fiscal Year 2021 Financial Results

  1/27/2022

  Quipt Home Medical Corp. today announced its fourth quarter and fiscal year 2021 financial results and operational highlights and filing of its annual financial statements.

• Nonagen Bioscience looks to Peregrine Market Access to lead the commercialization of innovative bladder cancer diagnostic test

  1/27/2022

  Peregrine Market Access, a leading life science commercialization partner, has been selected by Nonagen Bioscience to become its contract commercialization organization for Oncuria™, a breakthrough bladder cancer diagnostic test that is being developed to aid in detection, therapy choice, and disease monitoring.

• TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19

  1/27/2022

  TFF Pharmaceuticals, Inc. today announced that it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial (CT.gov identifier NCT05168644) of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases.

• Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants

  1/27/2022

  Indivior PLC (LON: INDV) today announced the publication of data from a clinical pharmacology study designed to assess the ability of buprenorphine to reduce respiratory depression and apnea associated with escalating doses of fentanyl administered in a clinical setting.